371 related articles for article (PubMed ID: 16517174)
21. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
22. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
23. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
24. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
[TBL] [Abstract][Full Text] [Related]
25. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
[TBL] [Abstract][Full Text] [Related]
26. Older age and second skin cancer as prognostic factors in localized malignant melanomas.
Brenner B; Borok S; Rakowsky E; Fenig E; Gutman H; Sulkes J; Sulkes A; Schachter J
Oncol Rep; 2003; 10(6):2051-7. PubMed ID: 14534742
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
28. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis.
Chagpar RB; Ross MI; Reintgen DS; Edwards MJ; Scoggins CR; Martin RC; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; McMasters KM
J Surg Res; 2007 Nov; 143(1):164-8. PubMed ID: 17950088
[TBL] [Abstract][Full Text] [Related]
30. Adolescent melanoma: risk factors and long term survival.
Daryanani D; Plukker JT; Nap RE; Kuiper H; Hoekstra HJ
Eur J Surg Oncol; 2006 Mar; 32(2):218-23. PubMed ID: 16412599
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo.
Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP
J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of serum VEGF in melanoma patients: a pilot study.
Ascierto PA; Leonardi E; Ottaiano A; Napolitano M; Scala S; Castello G
Anticancer Res; 2004; 24(6):4255-8. PubMed ID: 15736481
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
34. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
35. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
Mehta R; Shah G; Adler W; Kittur D
Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy and early-stage melanoma.
Daryanani D; Plukker JT; De Hullu JA; Kuiper H; Nap RE; Hoekstra HJ
Cancer; 2003 May; 97(9):2248-53. PubMed ID: 12712479
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of interleukin-2 soluble receptor in patients with trypanosomiasis americana in Panama].
Pascale JM; Sosa CE; Orn A
Rev Med Panama; 1991 Sep; 16(3):184-8. PubMed ID: 1767036
[TBL] [Abstract][Full Text] [Related]
38. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
39. [Determination of soluble interleukin-2 receptor in patients with American Trypanosomiasis in Panama].
Pascale JM; Sousa OE; Orn A
Rev Med Panama; 1992 Jan; 17(1):12-6. PubMed ID: 1603982
[TBL] [Abstract][Full Text] [Related]
40. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
